Related Experiment Video
Updated: Jul 21, 2026

09:29
Fabrication and Implantation of Miniature Dual-element Strain Gages for Measuring In Vivo Gastrointestinal Contractions in Rodents.
Published on: September 18, 2014
Effect of glucagon on esophageal motor function
Gastroenterology
|July 1, 1975
Summary
Exogenous glucagon can significantly decrease lower esophageal sphincter (LES) pressure at high doses. This inhibitory effect on LES pressure is pharmacological and not mediated by insulin or glucose changes.
Area of Science:
- Gastroenterology
- Endocrinology
- Pharmacology
Background:
- The lower esophageal sphincter (LES) plays a crucial role in preventing gastroesophageal reflux.
- Understanding factors that modulate LES pressure is important for managing esophageal disorders.
Purpose of the Study:
- To investigate the effect of exogenous glucagon on esophageal motor function, specifically LES pressure and esophageal peristalsis in humans.
- To determine if glucagon's effect on LES pressure is mediated by changes in serum insulin or glucose levels.
Main Methods:
- Manometric studies were conducted using an infused catheter system to monitor resting LES pressure.
- Intravenous pulse doses of glucagon were administered, and esophageal peristalsis was assessed.
- Blood samples were analyzed for glucagon, insulin, and glucose concentrations.
- Glucagon's effect was also evaluated during LES stimulation with pentagastrin.
Main Results:
- Glucagon caused a transient, significant decrease in LES pressure at high pulse doses (20 and 100 mug), leading to nonphysiological plasma glucagon levels.
- The reduction in LES pressure correlated with peak blood glucagon levels.
- Esophageal peristalsis was not demonstrably affected by glucagon.
- During pentagastrin-stimulated LES, glucagon induced significant transient decreases in LES pressure even at lower doses (1 mug/kg).
Conclusions:
- Exogenous glucagon exerts an inhibitory effect on LES pressure at pharmacologically relevant dosages.
- This inhibitory effect is independent of alterations in serum insulin or glucose.
- Glucagon's action on LES pressure appears to be a direct pharmacological effect.
More Related Videos
Related Concept Videos
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Gastric Motility
Gastric motility is the coordinated contraction and relaxation of stomach muscles that convert ingested food into chyme, a semi-liquid substance ready for further digestion in the intestines. The process begins with the vagus nerve inducing the relaxation of the smooth muscles in the fundus and body of the stomach, allowing these regions to expand and accommodate up to approximately 1.5 liters of food and liquid.
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Gastric Emptying
Gastric emptying occurs when the stomach gradually releases chyme into the duodenum. When the stomach is distended, it triggers the release of gastrin, a hormone that promotes gastric acid secretion to aid in digestion. Additionally, stomach distension contributes to peristaltic waves that propel gastric contents toward the pyloric region. The gastroenteric reflex, on the other hand, primarily stimulates peristalsis in the intestines, facilitating the movement of contents further along the...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Esophageal Achalasia
Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...

